Business Context and Reporting Period
Company: Baxter International Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Overview: Baxter is a global medical technology company providing essential healthcare products including sterile IV solutions, infusion systems, and pharmaceuticals. The company operates through three reportable segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. The reporting period reflects the completion of a major strategic transformation, including the sale of the Kidney Care business (completed January 31, 2025) and the implementation of a new operating model in 2023.
Key Financial Metrics
| Metric (in millions, except per share) | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net Sales | $10,636 | $10,360 | $10,057 |
| Gross Margin | $3,984 (37.5%) | $4,150 (40.1%) | $3,549 (35.3%) |
| Operating Income (Loss) | $14 | $707 | $(2,845) |
| Net Income (Loss) Attributable to Baxter | $(649) | $2,656 | $(2,433) |
| Diluted EPS (Total) | $(1.27) | $5.23 | $(4.83) |
| Operating Cash Flow (Continuing Ops) | $819 | $1,207 | $528 |
| Total Debt (Outstanding) | $13.13 billion | $13.76 billion | N/A |
| Cash and Cash Equivalents | $1.76 billion | $3.08 billion | $1.62 billion |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 3% to $10.64 billion, driven by growth in the Pharmaceuticals segment (+7%) and Medical Products & Therapies (+4%), partially offset by a decline in Healthcare Systems & Technologies (-2%).
- Profitability Decline: Net income swung to a loss of $649 million from a profit of $2.66 billion in 2023. This was primarily due to the absence of the $2.88 billion pre-tax gain from the 2023 sale of the BioPharma Solutions (BPS) business, which was reported as a discontinued operation.
- Special Items Impact: Continuing operations in 2024 were adversely impacted by $1.29 billion in special items, including a $425 million goodwill impairment (Front Line Care reporting unit), $110 million in Hurricane Helene costs, and $162 million in business optimization charges.
- Debt Reduction: The company paid down $3.65 billion of net debt during 2024 and early 2025 using proceeds from the BPS and Kidney Care sales. As of February 21, 2025, an additional $3.13 billion in debt was repaid.
- Dividend Reduction: In November 2024, the quarterly dividend was reduced from $0.29 to $0.17 per share in anticipation of the Kidney Care sale.
Guidance, Outlook, and Risks
- Strategic Actions: The sale of the Kidney Care business to Carlyle for approximately $3.80 billion was completed in January 2025. Proceeds are being used to deleverage the balance sheet, with a target net leverage ratio of approximately 3.0x by the end of 2025.
- Capital Allocation: The company intends to continue paying dividends but has suspended share repurchases during the deleveraging period. No share repurchases were made in 2024.
- Operational Challenges: Hurricane Helene caused significant disruption to the North Cove facility in North Carolina, resulting in $110 million in charges in 2024 and an estimated $50 million in additional charges expected in Q1 2025. Supply chain constraints and inflation continue to impact margins.
- Leadership Transition: In February 2025, José Almeida ceased serving as CEO. Brent Shafer was appointed Interim CEO, and a search for a permanent CEO has begun.
- Risks: Key risks include the successful integration of the Hillrom acquisition, potential dis-synergies from the Kidney Care sale, regulatory scrutiny (FDA warning letters regarding Indian facilities), and exposure to global economic conditions and currency fluctuations.
Investor Verification Checklist
- Debt Repayment Progress: Verify the extent of debt reduction achieved using Kidney Care proceeds and the trajectory toward the 3.0x net leverage target.
- North Cove Recovery: Monitor the timeline and cost of remediation for the North Cove facility and the impact on IV solution supply and margins in 2025.
- CEO Search: Track the timeline for appointing a permanent CEO and any associated leadership changes.
- Goodwill Impairments: Assess the risk of further goodwill impairments, particularly in the Healthcare Systems & Technologies segment, given the $425 million charge in 2024.
- Discontinued Operations: Confirm the final net proceeds from the Kidney Care sale and the classification of any remaining transition service costs.